Financial Analysis: Traws Pharma (NASDAQ:TRAW) versus Miravant Medical Technologies (OTCMKTS:MRVT)

Miravant Medical Technologies (OTCMKTS:MRVT) and Traws Pharma (NASDAQ:TRAW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Earnings & Valuation

This table compares Miravant Medical Technologies and Traws Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Miravant Medical Technologies	N/A	N/A	N/A	N/A	N/A
Traws Pharma	$230,000.00	39.26	-$166.52 million	$97.30	0.01

Miravant Medical Technologies has higher earnings, but lower revenue than Traws Pharma.

Institutional and Insider Ownership

8.0% of Traws Pharma shares are owned by institutional investors. 17.1% of Miravant Medical Technologies shares are owned by company insiders. Comparatively, 14.0% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Miravant Medical Technologies and Traws Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Miravant Medical Technologies	N/A	N/A	N/A
Traws Pharma	3,028.25%	-2,883.04%	512.82%

Analyst Ratings

This is a summary of current recommendations for Miravant Medical Technologies and Traws Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Miravant Medical Technologies	0	0	0	0	0.00
Traws Pharma	1	1	1	0	2.00

Traws Pharma has a consensus target price of $8.00, suggesting a potential upside of 607.96%. Given Traws Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Miravant Medical Technologies.

Summary

Traws Pharma beats Miravant Medical Technologies on 7 of the 9 factors compared between the two stocks.

About Miravant Medical Technologies

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.